Rivaroxaban is one of the new oral anticoagulants (NOACs) (recommended as reference treatments when a long-term anticoagulation is needed). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require biological monitoring. It is also characterized by less food and drug interactions. However, due to major risks associated with over- and under-dosage, its optimal use in patients should be carefully followed by health care professionals. The aim of this article is to provide recommendations for pharmacists on the practical use of Xarelto® in its different approved indications. This document is adapted from the practical user guide of rivaroxaban which was developed by an independent group of Belgian experts in the field of thrombosis and haemostasis.
|Translated title of the contribution||Rivaroxaban: Xarelto® - Recommendations for pharmacists|
|Number of pages||9|
|Journal||Journal de Pharmacie de Belgique|
|Publication status||Published - 1 Mar 2013|
- Venous Thrombosis
- Vitamin K
FingerprintDive into the research topics of 'Rivaroxaban: Xarelto® - Recommendations for pharmacists'. Together they form a unique fingerprint.
Evaluation of thrombotic and/or bleeding risks associated with anticoagulotherapy.Author: Douxfils, J., 24 Oct 2015
Supervisor: Dogne, J. (Supervisor), Mullier, F. (Supervisor), Masereel, B. (President), Chatelain, B. (Jury), Chatelain, C. (External person) (Jury), Verhamme, P. B. (External person) (Jury), TEN CATE, H. (External person) (Jury) & Ageno, W. (External person) (Jury)
Student thesis: Doc types › Doctor of Biomedical and Pharmaceutical Sciences